Ilagan, Crisanta H. http://orcid.org/0000-0001-7013-0634
Goldman, Debra A.
Gönen, Mithat
Aveson, Victoria G.
Babicky, Michelle
Balachandran, Vinod P.
Drebin, Jeffrey A.
Jarnagin, William R.
Wei, Alice C.
Kingham, T. Peter
Abou-Alfa, Ghassan K.
Brown, Karen T.
D’Angelica, Michael I.
Funding for this research was provided by:
NIH/NCI Cancer Center Support Grant (P30 CA008748)
Article History
Received: 26 January 2022
Accepted: 30 May 2022
First Online: 15 July 2022
Disclosure
: Ghassan K. Abou-Alfa reports research support from Arcus, Agios, Astra Zeneca, BioNtech, BMS, Celgene, Flatiron, Genentech/Roche, Genoscience, Incyte, Polaris, Puma, QED, Silenseed, and Yiviva, as well as consulting support from Adicet, Alnylam, Astra Zeneca, Autem, Bayer, Beigene, Berry Genomics, Celgene, Cend, CytomX, Eisai, Eli Lilly, Exelixis, Flatiron, Genentech/Roche, Genoscience, Helio, Incyte, Ipsen, Legend Biotech, Merck, Nerviano, QED, Redhill, Rafael, Servier, Silenseed, Sobi, Surface Oncology, Therabionics, Vector, and Yiviva (PCT/US2014/031545 filed on 24 March 2014, and priority application serial no. 61/804,907 filed 25 March 2013. Debra A. Goldman is a current employee of Regeneron Pharmaceuticals and receives restricted stock as a form of compensation. Alice C. Wei reports consulting for Histosonics, Biosapien; honorarium for teaching for Medtronic and AstraZeneca; and travel for Intuitive Surgical and Bayer. The remaining authors have no conflicts of interest.